HC Wainwright Has Negative Outlook for BCYC Q1 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for shares of Bicycle Therapeutics in a research note issued on Wednesday, February 26th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.99) per share for the quarter, down from their prior estimate of ($0.93). HC Wainwright currently has a "Buy" rating and a $33.00 target price on the stock. The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Bicycle Therapeutics' Q2 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.90) EPS, FY2026 earnings at ($4.31) EPS, FY2027 earnings at ($3.45) EPS, FY2028 earnings at ($1.56) EPS and FY2029 earnings at $1.20 EPS.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $3.70 million during the quarter, compared to analysts' expectations of $5.47 million. During the same quarter in the prior year, the firm earned ($1.16) EPS. The business's revenue for the quarter was down 30.2% compared to the same quarter last year.

Several other brokerages have also commented on BCYC. JMP Securities cut their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a research report on Wednesday, December 18th. B. Riley cut their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. Needham & Company LLC reissued a "buy" rating and issued a $30.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Finally, Stephens reissued an "equal weight" rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.14.

Bicycle Therapeutics Stock Down 4.6 %

Shares of NASDAQ BCYC traded down $0.50 during trading on Friday, reaching $10.47. The company had a trading volume of 173,771 shares, compared to its average volume of 298,289. The company's fifty day moving average price is $13.19 and its 200-day moving average price is $19.27. Bicycle Therapeutics has a 12 month low of $10.38 and a 12 month high of $28.67. The stock has a market cap of $722.91 million, a P/E ratio of -3.18 and a beta of 0.93.

Institutional Trading of Bicycle Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Assetmark Inc. bought a new stake in shares of Bicycle Therapeutics during the 3rd quarter valued at $34,000. Barclays PLC raised its stake in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after purchasing an additional 2,345 shares during the period. Avior Wealth Management LLC bought a new stake in shares of Bicycle Therapeutics during the 4th quarter valued at $57,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Bicycle Therapeutics by 30.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock valued at $131,000 after purchasing an additional 2,191 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after purchasing an additional 1,782 shares during the period. 86.15% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 9,038 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $127,345.42. Following the completion of the transaction, the chief executive officer now directly owns 495,026 shares of the company's stock, valued at approximately $6,974,916.34. This represents a 1.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Travis Alvin Thompson sold 2,686 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $15.00, for a total value of $40,290.00. Following the transaction, the chief accounting officer now directly owns 32,146 shares of the company's stock, valued at approximately $482,190. This trade represents a 7.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,677 shares of company stock valued at $392,413. Company insiders own 8.50% of the company's stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.